South Street Advisors LLC Bristol Myers Squibb CO Transaction History

South Street Advisors LLC

16 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 14, 2024	SELL	$48.48 - $57.85 $63,751 - $76,072	-1,315 Reduced 5.7%	21,770 $1.12 Million
Q2 2023 Aug 11, 2023	SELL	$63.71 - $70.74 $345,308 - $383,410	-5,420 Reduced 19.01%	23,085 $1.48 Million
Q1 2022 May 16, 2022	SELL	$61.48 - $73.72 $23,362 - $28,013	-380 Reduced 1.32%	28,505 $2.08 Million
Q4 2021 Feb 04, 2022	SELL	$53.63 - $62.52 $150,164 - $175,056	-2,800 Reduced 8.84%	28,885 $1.8 Million
Q2 2021 Aug 05, 2021	BUY	$61.91 - $67.42 $1.96 Million - $2.14 Million	31,685 New	31,685 $2.12 Million
Q1 2021 May 10, 2021	SELL	$59.34 - $66.74 $14.2 Million - $15.9 Million	-238,665 Closed	0 $0
Q4 2020 Feb 03, 2021	BUY	$57.74 - $65.43 $154,165 - $174,698	2,670 Added 1.13%	238,665 $14.8 Million
Q3 2020 Oct 26, 2020	BUY	$57.43 - $63.64 $1.61 Million - $1.78 Million	28,000 Added 13.46%	235,995 $14.2 Million
Q2 2020 Aug 04, 2020	BUY	$54.82 - $64.09 $11.4 Million - $13.3 Million	207,995 New	207,995 $12.2 Million
Q1 2020 May 08, 2020	SELL	$46.4 - $67.43 $151,728 - $220,496	-3,270 Closed	0 $0
Q4 2019 Feb 07, 2020	BUY	$49.21 - $64.19 $160,916 - $209,901	3,270 New	3,270 $210,000
Q4 2018 Feb 04, 2019	SELL	$48.76 - $63.23 $163,833 - $212,452	-3,360 Closed	0 $0
Q3 2018 Nov 14, 2018	BUY	$55.19 - $62.25 $185,438 - $209,160	3,360 New	3,360 $0
Q2 2018 Aug 15, 2018	SELL	$50.53 - $62.98 $178,876 - $222,949	-3,540 Closed	0 $0
Q4 2017 Feb 15, 2018	SELL	$59.94 - $65.35 $4,795 - $5,228	-80 Reduced 2.21%	3,540 $216,000
Q3 2017 Nov 15, 2017	BUY	$55.23 - $63.74 $199,932 - $230,738	3,620	3,620 $0

2,533

1.47B

31.6M

35M

Ticker BMY
Exchange NYSE
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 2,126,160,000
Market Cap $125B
Description
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple my...

Get notified when there are updates to the investment portfolio of South Street Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on South Street Advisors LLC with notifications on news.